This Slide: #44 of 83 |
Slide #44. PDL BioPharma — Type 2 diabetes products licensed by Depomed
Acquirer:
PDL BioPharma (PDLI)
Acquiree:
Type 2 diabetes products licensed by Depomed (DEPO)
Details:
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all payments received will be shared evenly between PDL and Depomed.
PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.
Open the PDLI Page at The Online Investor »
PDL BioPharma is engaged in providing alternative sources of capital through royalty monetizations and debt facilities; acquiring commercial-stage products and launching companies for commercialization of these products; as well as transactions involving late clinical-stage or early commercial-stage therapeutics. Co.'s subsidiary, LENSAR, Inc., is a medical device company focused on delivering femtosecond cataract laser technology used in refractive cataract surgical procedures. Co. also has investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health.
Open the DEPO Page at The Online Investor »
|
|
Free Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |